期刊
CLINICAL AND VACCINE IMMUNOLOGY
卷 17, 期 11, 页码 1817-1819出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/CVI.00461-09
关键词
-
资金
- Novartis Vaccines and Diagnostics
Immunogenicity and safety of a booster dose of an MF59-adjuvanted H5N1 vaccine containing 7.5 mu g A/turkey/Turkey/1/2005-like (clade 2.2) H5N1 hemagglutinin, given approximately 18 months after primary vaccination with a heterologous strain, were evaluated. The booster vaccine was well tolerated and induced a robust, cross-reactive immune response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据